Cargando…
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
In the current study, we examined whether the combination of tumor vasculature-targeted gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP-TNF-α) and/or the orally administered LCL161, an antagonist of inhibitors of apoptosis proteins (IAPs), enhanced antitumor effi...
Autores principales: | Yuan, Z, Syrkin, G, Adem, A, Geha, R, Pastoriza, J, Vrikshajanani, C, Smith, T, Quinn, T J, Alemu, G, Cho, H, Barrett, C J, Arap, W, Pasqualini, R, Libutti, S K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534156/ https://www.ncbi.nlm.nih.gov/pubmed/23154431 http://dx.doi.org/10.1038/cgt.2012.83 |
Ejemplares similares
-
IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022) -
Role of A20 in cIAP-2 Protection against Tumor Necrosis Factor α (TNF-α)-Mediated Apoptosis in Endothelial Cells
por: Guo, Shuzhen, et al.
Publicado: (2014) -
Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression
por: Beug, Shawn T., et al.
Publicado: (2018) -
IAP inhibitors enhance co-stimulation to promote tumor immunity
por: Dougan, Michael, et al.
Publicado: (2010) -
Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)